Overview
- Net sales reached €1,108.1 million in 2025, up 12.4%, marking the company’s first year above €1 billion.
- EBITDA rose 20.9% to €232.9 million as net profit jumped to about €46.1–46.2 million from roughly €10 million in 2024.
- Medical dermatology generated €669.4 million, up 22.1%, with Ilumetri at €234.4 million (+12.3%) and Ebglyss at €110.8 million (more than tripled) following key European launches.
- R&D spending totaled €138.1 million, or 12.5% of sales, with three Phase II trials under way and three additional Phase II studies planned within 12 months.
- The company reported a net-debt-to-EBITDA ratio of 0 after issuing a €250 million bond, and it guided for 2026 sales growth of 9–12% with EBITDA of €270–290 million.